Ireland
--:--IST
Latest
Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: Trade Data, Destination Markets, and Economic Impact Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: Trade Data, Destination Markets, and Economic Impact
Clinical Trials in Spain / NCT06342401
Recruiting Observational

Early Onset Colorectal Cancer Detection

NCT06342401 · tracked via the Priya Life Science Spain tracker
Sponsor
City of Hope Medical Center
Phase
Observational
Started
2023-04-15
Last updated
2026-07-07

Condition(s) studied

Colorectal CancerColorectal NeoplasmsColorectal AdenocarcinomaColorectal Cancer Stage IColorectal Cancer Stage IVColorectal Cancer Stage IIColorectal Cancer Stage IIIColorectal Neoplasms Malignant

Investigational drug(s) / intervention(s)

ENCODE

ENCODE: A panel of microRNA, both cell-free and exosomes, whose expression level is tested from plasma samples from patients with early onset colorectal cancer and non-disease controls.

Study summary

Colorectal cancer (CRC) once predominantly affected older individuals, but in recent years has witnessed a progressive increase in incidence among young adults. Once rare, early-onset colorectal cancer (EOCRC, that is, a CRC diagnosed before the age of 50) now constitutes 10-15% of all newly diagnosed CRC cases and it stands as the first cause of cancer-related death in young men and the second for young women.

This study aims to detect EOCRC with a non-invasive test, using a blood-based molecular assay based on microRNA (ribonucleic acid)

Eligibility

Sex
ALL
Min age
18 Years
Max age
50 Years
Healthy volunteers
Accepted
Inclusion Criteria: * Stage I, II, III, IV colorectal cancer (TNM classification, 8th edition) diagnosed before the age of 50 (EOCRC cases) * Received standard diagnostic and staging procedures as per local guidelines, and at least one sample was drawn before receiving any curative-intent treatment * Colonoscopy-proven cancer-free status at the time of study inclusion (Non-disease controls) Exclusion Criteria: * Hereditary colorectal cancer syndromes (identified through genetic testing) * Inflammatory bowel diseases * Lack of written informed consent

Primary outcome measure(s)

Trial sites (13)

FacilityCityRegionStatus
City of Hope Medical Center Duarte California Recruiting
IRCCS San Raffaele Milan Italy Recruiting
Kawasaki University Kawasaki Japan Recruiting
Mie University Mie Japan Recruiting
National Cancer Center Hospital Tokyo Japan Recruiting
Tokyo Medical and Dental University Tokyo Japan Recruiting
Yamagata University Yamagata Japan Recruiting
Barcelona University Barcelona Spain Recruiting
Colorectal Surgery, Vall d'Hebron University Hospital, Universitat Autonoma de Barcelona UAB Barcelona Spain Recruiting
Surgery Department, Hospital del Mar, Barcelona, Spain Barcelona Spain Recruiting
Salamanca Biomedical Research Institute Madrid Spain Recruiting
University of Salamanca-SACYL-CSIC, Salamanca, Spain Salamanca Spain Recruiting
University of La Laguna San Cristóbal de La Laguna Spain Recruiting

More City of Hope Medical Center trials in Spain

Stage II/III Colorectal Cancer Recurrence Recruiting
Early Detection of Advanced Adenomas and Colorectal Cancer Recruiting

Other trials for the same condition

Single cEll pRofiling PErsistaNce To ImmuNothErapy Recruiting
Impact of SMS Messaging on Participation in Colorectal Cancer Screening Recruiting
Basket Study of Entrectinib (RXDX-101) for the Treatment of Patients With Solid Tumors Harboring NTRK 1/2/3 (Trk A/B/C), ROS1, or ALK Gene Rearrangements (Fusions) Active, not recruiting
Early Diagnosis of Colorectal Cancer Based on a Non-invasive Metabolomics Profile Recruiting
European Polyp Surveillance Trial Active, not recruiting
Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT06342401 on ClinicalTrials.gov ↗ ← All trials in Spain